| 前收盘价格 | 6.97 |
| 收盘价格 | 6.97 |
| 成交量 | 227,318 |
| 平均成交量 (3个月) | 246,181 |
| 市值 | 154,117,232 |
| 价格/销量 (P/S) | 3.20 |
| 股市价格/股市净资产 (P/B) | 10.31 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 |
| 营业毛利率 | -27.34% |
| 营业利益率 (TTM) | -21.71% |
| 稀释每股收益 (EPS TTM) | -0.840 |
| 季度收入增长率 (YOY) | 7.50% |
| 总债务/股东权益 (D/E MRQ) | 367.92% |
| 流动比率 (MRQ) | 2.32 |
| 营业现金流 (OCF TTM) | -14.91 M |
| 杠杆自由现金流 (LFCF TTM) | -10.11 M |
| 资产报酬率 (ROA TTM) | -19.21% |
| 股东权益报酬率 (ROE TTM) | -117.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Exagen Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.9
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.88 |
|
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 19.82% |
| 机构持股比例 | 45.44% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 17.00 (Keybanc, 141.14%) | 购买 |
| 中 | 12.00 (70.21%) | |
| 低 | 11.00 (Canaccord Genuity, 56.03%) | 购买 |
| 平均值 | 13.33 (89.08%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 8.19 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 30 Jul 2025 | 11.00 (56.03%) | 购买 | 8.63 |
| Keybanc | 30 Jul 2025 | 17.00 (141.13%) | 购买 | 8.63 |
| Craig-Hallum | 23 Jul 2025 | 12.00 (70.21%) | 购买 | 7.32 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Aug 2025 | 公告 | Exagen Inc. to Participate in Third Quarter Investor Conferences |
| 29 Jul 2025 | 公告 | Exagen Inc. Reports Strong Q2 2025 Results |
| 17 Jul 2025 | 公告 | Exagen Inc. Appoints Chas McKhann to Board of Directors |
| 15 Jul 2025 | 公告 | Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 |
| 23 Jun 2025 | 公告 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合